Literature DB >> 2423089

Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.

C Lugnier, P Schoeffter, A Le Bec, E Strouthou, J C Stoclet.   

Abstract

Cyclic nucleotide phosphodiesterase (PDE) activity from the 105,000 g supernatant of human, bovine and rat aorta smooth muscle cells was resolved by DEAE-trisacryl chromatography into three major forms showing similar properties in each species. In addition to the two PDE forms previously characterized in vascular tissues (a cAMP-PDE and a calmodulin-dependent PDE), a cGMP-PDE, insensitive to calmodulin, was isolated and characterized in the aorta of the three species. Each isolated PDE form was differently inhibited by various chemical compounds, and these compounds produced effects on cyclic nucleotide levels in isolated rat aorta which could be expected from their inhibitory effect on isolated PDE forms. At concentrations non-selectively inhibiting the three isolated PDE forms (including the calmodulin-dependent one), IBMX (3-isobutyl-1-methylxanthine) and trequinsin markedly and dose-dependently increased both cAMP and cGMP aorta levels (up to 7-fold, in presence of 500 microM IBMX). By contrast selective inhibitors of cGMP-PDE or cAMP-PDE could only induce a moderate elevation (by 1.5-3-fold) in cGMP or cAMP levels, respectively. In the case of M&B 22,948, a highly specific and potent inhibitor of cGMP-PDE, a concentration-dependent increase in tissue cGMP levels was produced by concentrations (in the microM range) active in inhibiting the isolated enzyme. In the case of selective cAMP-PDE inhibitors (rolipram and Ro 20-1724), however, a significant increase in aorta cAMP content was induced only in the presence of drug concentrations which were much higher (200 and 500 microM, respectively) than those inhibiting the isolated enzyme (IC50:5 and 18 microM, respectively). Inhibitors of both cGMP-PDE and cAMP-PDE (dipyridamole, cilostamide and its derivative AAL 05) produced the same moderate effects as did the combination of a selective cGMP-PDE inhibitor and a selective cAMP-PDE inhibitor on the levels of both cGMP and cAMP. These results show that the three forms of PDE isolated from aortic smooth muscle retain properties that they exhibit in the tissue and which are similar in the three species examined, including man. They suggest that each form participates in a specific manner to the regulation of cAMP and cGMP concentrations in aorta smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423089     DOI: 10.1016/0006-2952(86)90333-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  61 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

3.  Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo.

Authors:  S Moncada; D D Rees; R Schulz; R M Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 4.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

5.  Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta.

Authors:  Ezequiel Alvarez; Manuel Campos-Toimil; Hélène Justiniano-Basaran; Claire Lugnier; Francisco Orallo
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality.

Authors:  I Sturgess; G F Searle
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

7.  Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS.

Authors:  E Butt; D Pöhler; H G Genieser; J P Huggins; B Bucher
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma.

Authors:  Hyung-Geun Moon; You-Sun Kim; Jun-Pyo Choi; Dong-Sic Choi; Chang Min Yoon; Seong Gyu Jeon; Yong Song Gho; Yoon-Keun Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

9.  Heterogeneity of pulmonary endothelial cyclic nucleotide response to Pseudomonas aeruginosa ExoY infection.

Authors:  K A Morrow; R Seifert; V Kaever; A L Britain; S L Sayner; C D Ochoa; E A Cioffi; D W Frank; T C Rich; T Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-18       Impact factor: 5.464

Review 10.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.